Tegoprubart: A Next-Generation Anti-Rejection Therapy
Before 1994, kidney transplant failure within five years was common. Tacrolimus improved survival, but serious side effects and long-term organ damage became widely accepted as inevitable. Now, a new drug suggests transplant medicine may be entering its next phase without the same cost to the body…
Inside UCLA’s Effort to End Required Lifelong Transplant Anti-Rejection Drugs
For decades, surviving a transplant has meant taking powerful anti-rejection drugs for life. A UCLA clinical trial using donor stem cells is testing whether retraining the immune system could finally change that tradeoff…